Dr. Gibson is Professor at the University of British Columbia in Canada. She is a translational scientist who studies how the gut microbiome develops in response to the environmental cues, like dietary patterns, and how this drives immunometabolic responses. She is the co-founder, past Chief Scientific Officer and current non-executive Chief Science Advisor of Melius MicroBiomics (MMB). Her inventions form the basis of the spin off company out of UBC which has licensed the patent out to MMB. Her research group creates and tests genetically engineered microbial medicines to treat IBD and other chronic diseases in pre-clinical models intended to be developed and commercialized in MMB. She is actively involved in the biotechnology holding several board director positions helping shape the strategic directions and decision-making in industry. She is currently the past chair for the Crohn’s and Colitis Canada Scientific and Medical Advisory Council from her tenure as chair and board director from 2022-2025 for Crohn’s and Colitis Canada.
Awards:
- Women in IBD Researcher of the Year Award (Crohn’s and Colitis Canada) – 2025
- CIHR Institute of Nutrition, Metabolism and Diabetes Community Support Program Award: New Investigator Partnership Prize (CIHR) – 2018
- Canadian Association of Gastroenterology Young Investigator research award (Canadian Association of Gastroenterology) – 2018
- Killam Faculty Research Fellowship (UBC) – 2017
- Top 10 New Investigator Award (International Society for the Study of Fatty Acids and Lipids: 2014 Biennial Congress) – 2014
- Early Career Award (NSERC) – 2012-2017
- Postdoctoral Fellowship (Michael Smith Foundation for Health Research) – 2007-2010
- Postdoctoral Fellowship (CIHR / Canadian Association of Gastroenterology / Astrazenica) – 2006-2010
- Postgraduate Scholarship (NSERC) – 2003-2005